RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

BackgroundAdjuvant chemotherapy is a major adjuvant treatment modality for hormonal receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients derive practical benefits. How to balance its potential benefits and risks becomes a challenging clinical problem. The purpose...

Full description

Bibliographic Details
Main Authors: Haibo Wang, Li Ma, Yanan Zhang, Ouchen Wang, Zhimin Wei, Xiaohong Xie, Xiaoming Zha, Jian Zeng, Qing Lv, Yu Ren, Huimin Wang, Furong Du, Shangzhi Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
Early breast cancer
Luminal type
RecurIndex assay
Adjuvant chemotherapy
Survival outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.896431/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.896431/full

Similar Items